Clinical Trial Update: Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ibrutinib in combination with rituximab in previously untreated follicular lymphoma shows completed status with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Follicular Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)
• Rituximab (rituximab)

Snippet

Sponsor: Pharmacyclics LLC. | Conditions: Follicular Lymphoma, B-cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2019-04-16